Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Annals of Surgery|July 14, 2022
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) ResultsDario Callegaro, Chandrajit P Raut, Taiwo Ajayi, et al.
JAMA Surgery|September 17, 2025
Diagnostic Accuracy of Imaging in Assessing Nonviability of Disappearing Colorectal Liver MetastasisKozo Kataoka, Murielle Mauer, Manabu Shiozawa, et al.
Lancet (London, England)|May 19, 2012
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T A van der Graaf, Jean-Yves Blay, Sant P Chawla, et al.
The Lancet. Oncology|December 16, 2014
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialCora N Sternberg, Iwona Skoneczna, J Martijn Kerst, et al.
The Lancet. Oncology|September 17, 2020
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trialSylvie Bonvalot, Alessandro Gronchi, Cécile Le Péchoux, et al.
The New England Journal of Medicine|April 17, 2018
Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaAlexander M M Eggermont, Christian U Blank, Mario Mandala, et al.
European Journal of Cancer (Oxford, England : 1990)|September 17, 2024
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trialAlexander Mm Eggermont, Michal Kicinski, Christian U Blank, et al.
JAMA Oncology|January 3, 2020
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical TrialAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
NEJM Evidence|February 6, 2024
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III MelanomaAlexander M M Eggermont, Michal Kicinski, Christian U Blank, et al.
Pageof 7